ADMA (ADMA) CEO net-sells 21K shares under 10b5-1 plan

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman reported a mix of option exercise and share sales. On February 17, 2026, he exercised a stock option for 15,000 shares at $5.40 per share, converting it into 15,000 shares of common stock. He then sold a total of 21,000 common shares in open-market transactions at $16.08 per share under a Rule 10b5-1 trading plan.

After these transactions, he directly holds 2,284,379 common shares. He also has indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC. Footnotes note multiple unvested RSU awards granted between 2022 and 2026 that vest over four years and settle in common stock, plus previously acquired shares reflecting prior RSU vesting and purchases.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M		15,000(1)	A	$5.4	2,305,379	D
Common Stock	02/17/2026		S		15,000(1)	D	$16.08(2)	2,290,379	D
Common Stock	02/17/2026		S		6,000(1)	D	$16.08(2)	2,284,379(3)(4)(5)	D
Common Stock								1,143,426	I	See Footnote(6)
Common Stock								580,957	I	See Footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.4	02/17/2026		M			15,000(1)	(8)	02/26/2034	Common Stock	15,000	$0	705,950	D

Explanation of Responses:

1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

2. The price reported in Column 4 is the price at which the shares were sold.

3. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

5. (continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ADMA (ADMA) CEO Adam Grossman report in this Form 4?

Adam Grossman reported an option exercise and share sales. He converted 15,000 option shares into common stock, then sold 21,000 common shares in open-market trades executed under a pre-arranged Rule 10b5-1 trading plan.

How many ADMA shares did the CEO sell and at what price?

The CEO sold a total of 21,000 ADMA common shares. The reported sale price was $16.08 per share in open-market or private transactions on February 17, 2026, as disclosed in the Form 4 footnotes and transaction details.

How many ADMA shares does the CEO own after these transactions?

After the transactions, Adam Grossman directly owns 2,284,379 ADMA common shares. He also has indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, according to the reported holdings information.

What stock option activity did the ADMA CEO report?

He exercised a stock option for 15,000 shares of ADMA common stock. The option had an exercise price of $5.40 per share and was reported as an exercise or conversion of a derivative security on February 17, 2026.

What is the Rule 10b5-1 trading plan mentioned in the ADMA filing?

The filing states the sales were made under a Rule 10b5-1 plan. This plan, entered with Fidelity on November 14, 2025, pre-scheduled trades in advance, allowing the CEO’s share sales to follow a predetermined program.

What unvested RSUs does the ADMA CEO hold according to the Form 4?

Footnotes describe several unvested RSU grants from 2022 to 2026. These include awards such as 282,529 RSUs granted February 9, 2026 and other large tranches, all vesting over four years and settling in ADMA common stock upon vesting.